Skip to main content
Premium Trial:

Request an Annual Quote

Bayer CropScience, Evogene Ink Alliance

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Bayer CropScience and Evogene today announced that they have entered into a five-year genomics research alliance aimed at accelerating the development and introduction of improved wheat varieties.

The firms will use Evogene's Athlete, RePack, and EvoBreed computational genomic technologies to identify genetically modified and native traits to improve yield, drought tolerance, fertilizer utilization, and other characteristics. The collaboration builds on an earlier alliance between the firms focused on increasing rice productivity and yield.

Rehovot, Israel-based Evogene will receive around $20 million in upfront fees and annual research payments over the term of the agreement. In addition, it will receive development milestone payments and royalties on the commercialization of any resulting products. Further details of the agreement were not disclosed.

Bayer CropScience also will make an equity investment of $12 million in Evogene at a price of approximately $7 per ordinary share.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.